A double-blind, randomized, parallel-group, placebo-controlled, multiple-dose study to assess the effect of 125 mg/day orally administered azimilide dihydrochloride on renal function and hemodynamics in healthy volunteers

Trial Profile

A double-blind, randomized, parallel-group, placebo-controlled, multiple-dose study to assess the effect of 125 mg/day orally administered azimilide dihydrochloride on renal function and hemodynamics in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Azimilide (Primary)
  • Indications Arrhythmias
  • Focus Pharmacodynamics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 10 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top